Skip to content
Research Article Open access CC BY 4.0

Insulin Resistance in Egyptian Nonalcoholic Fatty Liver Disease patients

Amal Ahmed Mohamed, Wafaa Gh. Shousha, Olfat Shaker, Mohamed El-Sayed Mahdy, Eman M. A. Ibrahim, Hala Abd AL Aal, Ahmed Abdel Hamid, Marwa Azzat, Amal El Shimy

Journal of Advances in Medicine and Medical Research · pp. 463–473 · Published 27 Dec 2014

10.9734/BJMMR/2015/11380

Abstract

Background: The liver has been recognized as a major target of injury in patients with insulin resistance or the metabolic syndrome. Insulin resistance is associated with fat accumulation in the liver, a condition called nonalcoholic fatty liver disease (NAFLD). NAFLD is a clinicopathologic entity that includes a spectrum of liver damage ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), advanced fibrosis, and rarely, progression to cirrhosis. Recent studies emphasize the role of insulin resistance, oxidative stress and subsequent lipid peroxidation, proinflammatory cytokines, adipokines and mitochondrial dysfunction in the development and progression of NAFLD. About 20% all adults have NAFLD and 2% to 3% of adults have NASH. A strong correlation exists between overweight, in particular visceral fat accumulation, and prevalence of NASH. Aim: "This study aimed at assessing the effect of insulin resistance in a sample of Egyptian patients with non-Alcoholic fatty liver". Methods: This study was conducted on 2 groups 104 NAFLD as diagnosed by ultrasound examination and 21 healthy participants as control group. All the participants were subjected to an abdominal ultrasonography, liver enzymes, lipid profile (triglycerides, HDL, LDL cholesterol), glucose and fasting insulin. Results: The blood sugar and fasting insulin levels were significantly higher in NAFLD patients than control group (172.81±35.47 mg/ml vs 101.33±11.95 mg/ml and11.72±4.7 U/ml vs 5.93±4.68) respectively. 88.5% of NAFLD patients were obese (BMI ≥ 30) and 11.5% were over weight (BMI < 30) while 23.8% were obese and 76.2% were overweight for control group. HOMA-IR was significantly higher in NAFLD patients than in healthy controls (5.02±2.39 vs. 1.41±1.20; P<0.001). We found 81.7% of the studied patients fulfilled the metabolic syndrome criteria while 9.5% for controls. HOMA-IR ROC curve showed 94.23% sensitivity and 85.71 specificity in NAFLD group. Fasting Insulin ROC curve showed 91.35% sensitivity and 80.95% specificity in NAFLD group. Conclusion: Patients with NAFLD have higher insulin resistance and have higher lipid profile, ALT & AST levels compared with their control group. Also the Ratio of the metabolic syndrome was higher in the NAFLD patients (81.7%).

Non alcoholic fatty liver disease non alcoholic steatohepatitis insulin resistance and metabolic syndrome

References (56)

  1. 1 Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge [DOI]
  2. 2 Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man [DOI]
  3. 3 Prevalence and Trends in Obesity Among US Adults, 1999-2008 [DOI]
  4. 4 Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010 [DOI]
  5. 5 Nonalcoholic Fatty Liver Disease [DOI]
  6. 6 The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association [DOI]
  7. 7 Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults [DOI]
  8. 8 The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study [DOI]
  9. 9 Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome [DOI]
  10. 10 Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis [DOI]
  11. 11 Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic, and Clinical Implications [DOI]
  12. 12 Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis [DOI]
  13. 13 Association of nonalcoholic fatty liver disease with insulin resistance [DOI]
  14. 14 Prevalence of and Risk Factors for Nonalcoholic Fatty Liver Disease: The Dionysos Nutrition and Liver Study * # [DOI]
  15. 15 AGA technical review on nonalcoholic fatty liver disease [DOI]
  16. 16 A position statement on NAFLD/NASH based on the EASL 2009 special conference [DOI]
  17. 17 Role of Insulin Resistance in Human Disease (Syndrome X): An Expanded Definition [DOI]
  18. 18 Ultrasound scanning in the detection of hepatic fibrosis and steatosis. [DOI]
  19. 19 Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms [DOI]
  20. 20 Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression [DOI]
  21. 21 Adipose Tissue Dysfunction in Obesity [DOI]
  22. 22 Metabolic Syndrome: A Clinical and Molecular Perspective [DOI]
  23. 23 Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States [DOI]
  24. 24 Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints [DOI]
  25. 25 Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease [DOI]
  26. 26 Metabolic Significance of Nonalcoholic Fatty Liver Disease in Nonobese, Nondiabetic Adults [DOI]
  27. 27 Elevations in Markers of Liver Injury and Risk of Type 2 Diabetes [DOI]
  28. 28 Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease in an Adult Population of Taiwan: Metabolic Significance of Nonalcoholic Fatty Liver Disease in Nonobese Adults [DOI]
  29. 29 Nonalcoholic Fatty Liver Disease: A Clinical Review [DOI]
  30. 30 Review article: current management of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis [DOI]
  31. 31 Cardiac Abnormalities as a New Manifestation of Nonalcoholic Fatty Liver Disease: Echocardiographic and Tissue Doppler Imaging Assessment [DOI]
  32. 32 Gender, socio-economic status and metabolic syndrome in middle-aged and old adults [DOI]
  33. 33 Fatty Liver, Insulin Resistance, and Features of Metabolic Syndrome [DOI]
  34. 34 Epidemiology of the metabolic syndrome in the USA [DOI]
  35. 35 Non Alcoholic Fatty Liver Disease in Southern Iran: A Population Based Study [DOI]
  36. 36 Alarming predictions for obesity and non-communicable diseases in the Middle East [DOI]
  37. 37 New aspects of the insulin resistance syndrome: impact on haematological parameters [DOI]
  38. 38 The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study [DOI]
  39. 39 Homeostasis model assessment of insulin resistance for evaluating insulin sensitivity in patients with type 2 diabetes on insulin therapy [DOI]
  40. 40 Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China.
  41. 41 Non-alcoholic fatty liver disease (NAFLD)--the hepatic component of metabolic syndrome.
  42. 42 Non-Alcoholic Fatty Liver Disease Is Closely Associated with Sub-Clinical Inflammation: A Case-Control Study on Asian Indians in North India [DOI]
  43. 43 Fatty liver disease: the hepatic manifestation of metabolic syndrome [DOI]
  44. 44 Why a Cluster is Truly a Cluster: Insulin Resistance and Cardiovascular Disease [DOI]
  45. 45 NAFLD and Insulin Resistance Do Not Increase the Risk of Postoperative Complications Among Patients Undergoing Bariatric Surgery—A Prospective Analysis [DOI]
  46. 46 Serum α-fetoprotein levels in liver steatosis [DOI]
  47. 47 Metabolic syndrome, non-alcoholic steatohepatitis (NASH), and hepatocyte growth factor (HGF) [DOI]
  48. 48 PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE AND ASSOCIATED RISK FACTORS AMONG MANAGERS FROM THE COMMUNITY OF MADRID [DOI]
  49. 49 Stéatohépatite métabolique : 30 ans de recherches qui ont changé la NASH [DOI]
  50. 50 Nonalcoholic Fatty Liver Disease [DOI]
  51. 51 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [DOI]
  52. 52 Prevalence and Trends in Obesity Among US Adults, 1999-2000 [DOI]
  53. 53 Nonalcoholic Fatty Liver Disease [DOI]
  54. 54 The IDF consensus worldwide definition of the metabolic syndrome [DOI]
  55. 55 A Study of Non-Alcoholic Fatty Liver Disease (Nafld) in Type 2 Diabetes Mellitus in a Tertiary Care Centre, Southern India
  56. 56 JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH [DOI]

Cited by 3

Non Alcoholic Fatty Liver Disease and Degree of Steatosis in Diabetic and Non- Diabetic patients

Ghada M. Khafagy, Hatem A. Darwish, Ayman Yosry · Obesity Medicine · 2020

Showing 1 of 3 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

32

Page views

0

PDF downloads

10

Outbound clicks

3

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.